Advertisement

Gene Expression Profiles in Cutaneous Oncology

Published:October 27, 2022DOI:https://doi.org/10.1016/j.det.2022.07.018

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Apalla Z.
        • et al.
        Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches.
        Dermatol Ther (Heidelb). 2017; 7: 5-19
        • Rogers H.W.
        • et al.
        Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the us population, 2012.
        JAMA Dermatol. 2015; 151: 1081-1086
        • Guy G.P.
        • et al.
        Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.
        Am J Prev Med. 2015; 48: 183-187
        • Rashmi Kumar N.
        • et al.
        NCCN Guidelines Version 2.2022 Breast Cancer.
        (Available at:)
        • Freedman-Cass D.
        • et al.
        NCCN Guidelines Version 3.2022 Prostate Cancer.
        (Available at:)
        • Wysong A.
        • et al.
        Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
        J Am Acad Dermatol. 2020; https://doi.org/10.1016/j.jaad.2020.04.088
        • Gerami P.
        • et al.
        Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
        Clin Cancer Res. 2015; 21: 175-183
        • Joseph M.G.
        • et al.
        Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome.
        Aust N Z J Surg. 1992; 62: 697-701
        • Brougham N.D.L.S.
        • et al.
        The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors.
        J Surg Oncol. 2012; 106: 811-815
        • Mai Nguyen N.
        • et al.
        NCCN Squamous Cell Skin Cancer Guidelines Version 1.2022.
        (Available at:)
        • Amin M.B.
        • et al.
        Amin M.B. Edge S.B. Greene F.L. AJCC cancer staging manual. 8th edition. Springer International Publishing, 2017
        • Jambusaria-Pahlajani A.
        • et al.
        Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
        JAMA Dermatol. 2013; 149: 402-410
        • Farberg A.S.
        • Fitzgerald A.L.
        • Ibrahim S.F.
        • et al.
        Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC): a narrative review.
        Dermatol Ther (Heidelb). 2022; 12: 267-284
        • Farberg A.S.
        • et al.
        Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
        Curr Med Res Opin. 2020; 36: 1301-1307
        • Litchman G.H.
        • et al.
        Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
        Curr Med Res Opin. 2020; 36: 1295-1300
        • Mullen J.T.
        • et al.
        Invasive squamous cell carcinoma of the skin: defining a high-risk group.
        Ann Surg Oncol. 2006; 13: 902-909
        • Haisma M.S.
        • et al.
        Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
        J Am Acad Dermatol. 2016; 75: 722-730
        • Waldman A.
        • et al.
        Cutaneous squamous cell carcinoma.
        Hematol Oncol Clin North Am. 2019; 33: 1-12
        • Edkins O.
        • et al.
        Does sentinel lymph node biopsy have a role in node-positive head and neck squamous carcinoma?.
        S Afr J Surg. 2013; 51: 22-25
        • Ahadiat O.
        • et al.
        SLNB in cutaneous SCC: a review of the current state of literature and the direction for the future.
        J Surg Oncol. 2017; 116: 344-350
        • Michna A.
        • et al.
        Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.
        Radiat Oncol. 2016; 11https://doi.org/10.1186/s13014-016-0672-0
        • Chaudhry M.A.
        Analysis of gene expression in normal and cancer cells exposed to γ-radiation.
        J Biomed Biotechnol. 2008; 2008https://doi.org/10.1155/2008/541678
        • Baker J.B.
        • et al.
        Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.
        Br J Cancer. 2011; 104: 488-495
        • Bailey P.
        • et al.
        Genomic analyses identify molecular subtypes of pancreatic cancer.
        Nature. 2016; 531: 47-52
        • Migden M.R.
        • et al.
        Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
        Lancet Oncol. 2020; 21: 294-305
        • Grob J.J.
        • et al.
        Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629).
        J Clin Oncol. 2020; 38: 2916-2925
        • Xu M.
        • et al.
        Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
        BMC Cancer. 2019; 19https://doi.org/10.1186/s12885-019-5808-9
        • Lindelöf B.
        • et al.
        Incidence of skin cancer in 5356 patients following organ transplantation.
        Br J Dermatol. 2000; 143: 513-519
        • Genders R.E.
        • et al.
        Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta-analysis.
        J Eur Acad Dermatol Venereol. 2019; 33: 828-841
        • Feldmeyer L.
        • et al.
        Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals.
        Exp Dermatol. 2016; 25https://doi.org/10.1111/exd.12878
        • Lobl M.B.
        • et al.
        The correlation of immune status with ultraviolet radiation–associated mutations in cutaneous squamous cell carcinoma: a case-control study.
        J Am Acad Dermatol. 2020; 82: 1230-1232
        • Muehleisen B.
        • et al.
        Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients.
        PLoS One. 2012; 7https://doi.org/10.1371/journal.pone.0040754
        • Ali Z.
        • et al.
        Melanoma epidemiology, biology and prognosis.
        EJC Suppl. 2013; 11: 81-91
        • Dooley T.P.
        • et al.
        Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR.
        Biochem Biophysical Res Commun. 2003; 306: 1026-1036
        • Elmore J.G.
        • et al.
        Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study.
        BMJ (Online). 2017; 357https://doi.org/10.1136/bmj.j2813
        • Gerami P.
        • et al.
        Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma.
        J Am Acad Dermatol. 2017; 76: 114-120.e2
      1. Brouha B., Ferris L., Skelsey M., et al., Genomic atypia to enrich melanoma positivity in biopsied lesions: gene expression and pathology findings from a large US registry study, SKIN J Cutan Med Surg, 5 (1), 2021, 13-18.

        • Nault A.
        • et al.
        Biopsy use in skin cancer diagnosis: comparing dermatology physicians and advanced practice professionals.
        JAMA Dermatol. 2015; 151: 899-902
        • Skelsey M.
        • Brouha B.
        • Rock J.
        • et al.
        Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden.
        SKIN J Cutan Med Surg. 2021; 5: 512-523
      2. Cullison S.R., Jansen B., Yao Z., et al., Risk Stratification of Severely Dysplastic Nevi by Non-Invasively Obtained Gene Expression and Mutation Analyses, SKIN J Cutan Med Surg, 4 (2), 2020, 124-129.

        • Clarke L.E.
        • et al.
        Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
        J Cutan Pathol. 2015; 42: 244-252
        • Clarke L.E.
        • et al.
        An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
        Cancer. 2017; 123: 617-628
        • Gershenwald J.E.
        • et al.
        Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
        CA: A Cancer J Clinicians. 2017; 67: 472-492
        • Ferris L.K.
        • et al.
        Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification.
        J Am Acad Dermatol. 2017; 76: 818-825.e3
        • Jaeger J.
        • et al.
        Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
        Clin Cancer Res. 2007; 13: 806-815
        • Bittner M.
        • et al.
        Molecular classification of cutaneous malignant melanoma by gene expression profiling.
        Nature. 2000; 406: 536-540
        • Smith A.P.
        • et al.
        Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
        Cancer Biol Ther. 2005; 4: 1018-1029https://doi.org/10.4161/cbt.4.9.2165
        • Haqq C.
        • et al.
        The gene expression signatures of melanoma progression.
        Proc Natl Acad Sci U S A. 2005; 102: 6092-6097
        • Mauerer A.
        • et al.
        Identification of new genes associated with melanoma.
        Exp Dermatol. 2011; 20: 502-507
        • Scatolini M.
        • et al.
        Altered molecular pathways in melanocytic lesions.
        Int J Cancer. 2010; 126: 1869-1881
        • Scott A.M.
        • et al.
        Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma.
        Am Surg. 2020; 86: 1561-1564
        • Hsueh E.C.
        • et al.
        Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma.
        JCO Precis Oncol. 2021; 5: 00119
        • Greenhaw B.N.
        • et al.
        Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
        J Am Acad Dermatol. 2020; 83: 745-753
        • Gastman B.R.
        • et al.
        Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
        Head and Neck. 2019; 41: 871-879
        • Keller J.
        • et al.
        Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
        Cancer Med. 2019; 8: 2205-2212
        • Zager J.S.
        • et al.
        Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
        BMC Cancer. 2018; 18https://doi.org/10.1186/s12885-018-4016-3
        • Hsueh E.C.
        • et al.
        Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
        J Hematol Oncol. 2017; 10https://doi.org/10.1186/s13045-017-0520-1
        • National Comprehensive Cancer Network
        NCCN Clinical Practice Guidelines in Oncology Melanoma: Cutaneous.
        (Available at:)
        • Swetter S.M.
        • et al.
        Melanoma: cutaneous, version 2.2021 featured updates to the NCCN guidelines.
        JNCCN J Natl Compr Cancer Netw. 2021; 19: 364-376
        • Gastman B.R.
        • et al.
        Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
        J Am Acad Dermatol. 2019; 80: 149-157.e4
        • Marchetti M.A.
        • et al.
        Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis.
        JAMA Dermatol. 2020; 156: 953-962
        • Svoboda R.M.
        • et al.
        Factors affecting dermatologists’ use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma.
        J Drugs Dermatol. 2018; 17: 544-547
        • Berger A.C.
        • et al.
        Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients.
        Curr Med Res Opin. 2016; 32: 1599-1604
        • Mbbs D.S.
        • et al.
        Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging.
        J Drugs Dermatol. 2018; 17: 196-199
        • Farberg A.S.
        • et al.
        Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists’ clinical management decisions.
        J Drugs Dermatol. 2017; 16: 428-431
        • Eggermont A.M.M.
        • et al.
        Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy.
        New Engl J Med. 2016; 375: 1845-1855
        • Mulder E.E.A.P.
        • et al.
        Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
        Br J Dermatol. 2021; 184: 944-951
        • Gambichler T.
        • et al.
        Gene-signature based prediction of relapse-free survival in melanoma patients with known sentinel lymph node status.
        J Clin Oncol. 2017; 35: e21037
        • Amaral T.M.S.
        • et al.
        Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
        Eur J Cancer. 2020; 125: 38-45
        • Grossman D.
        • et al.
        Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit.
        JAMA Dermatol. 2020; 156: 1004-1011
        • Swetter S.M.
        • et al.
        Guidelines of care for the management of primary cutaneous melanoma.
        J Am Acad Dermatol. 2019; 80: 208-250
        • Grossman D.
        • et al.
        Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice.
        Melanoma Management. 2019; 6: MMT32
        • Inman G.J.
        • et al.
        The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
        Nat Commun. 2018; 9: 3667
        • Lobl M.
        • et al.
        Basal cell carcinoma gene mutations differ between Asian, Hispanic, and Caucasian patients: a pilot study.
        J Drugs Dermatol. 2021; 20: 504-510
        • Ibrahim S.F.
        • et al.
        Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
        Future Oncol. 2021; (Published online November 25)https://doi.org/10.2217/fon-2021-1277
        • Podlipnik S.
        • et al.
        Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
        J Eur Acad Dermatol Venereol. 2019; 33: 857-862
        • Greenhaw B.N.
        • et al.
        Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test.
        Dermatol Surg. 2018; 44: 1494-1500
        • Eggermont A.M.M.
        • et al.
        Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
        Eur J Cancer. 2020; 140: 11-18
        • Koelblinger P.
        • et al.
        A prognostic gene-signature based identification of high-risk thin melanomas.
        J Clin Oncol. 2018; 36: e21575
        • Reschke R.
        • et al.
        Identifying high-risk tumors within AJCC stage IB–III melanomas using a seven-marker immunohistochemical signature.
        Cancers (Basel). 2021; 13: 2902